Acute supra-therapeutic oral terbutaline administration has no ergogenic effect in non-asthmatic athletes

This study aimed to investigate the effects on a possible improvement in aerobic and anaerobic performance of oral terbutaline (TER) at a supra-therapeutic dose in 7 healthy competitive male athletes. On day 1, ventilatory threshold, maximum oxygen uptake and corresponding power output were measured...

Full description

Saved in:
Bibliographic Details
Published in:European journal of applied physiology Vol. 113; no. 2; pp. 411 - 418
Main Authors: Sanchez, Anthony M. J., Borrani, Fabio, Le Fur, Marie Amélie, Le Mieux, Anais, Lecoultre, Virgile, Py, Guillaume, Gernigon, Christophe, Collomp, Katia, Candau, Robin
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer-Verlag 01.02.2013
Springer Nature B.V
Springer Verlag
Subjects:
Administration, Oral
Adrenergic beta-2 Receptor Agonists - administration & dosage
Adult
Asthma
Asthma - drug therapy
Asthma - physiopathology
Athletic Performance - physiology
Biomedical and Life Sciences
Biomedicine
Bronchodilator Agents - administration & dosage
Double-Blind Method
Drug dosages
Exercise
Human Physiology
Humans
Life Sciences
Male
Occupational Medicine/Industrial Medicine
Original Article
Performance-Enhancing Substances - administration & dosage
Physical Endurance - drug effects
Physical Endurance - physiology
Physical fitness
Sports Medicine
Terbutaline - administration & dosage
Treatment Outcome
France
β
Agonist
Anaerobic performance
Healthy athletes
Doping
Force–velocity relationship
Endurance performance
ENDURANCE
CLENBUTEROL
Force-velocity relationship
PERFORMANCE
beta-Agonist
EXERCISE
SKELETAL-MUSCLE
HYPERTROPHY
IMPACT
POWER OUTPUT
TERM SALBUTAMOL INGESTION
WINGATE TEST
ISSN:1439-6319, 1439-6327, 1439-6327
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to investigate the effects on a possible improvement in aerobic and anaerobic performance of oral terbutaline (TER) at a supra-therapeutic dose in 7 healthy competitive male athletes. On day 1, ventilatory threshold, maximum oxygen uptake and corresponding power output were measured and used to determine the exercise load on days 2 and 3. On days 2 and 3, 8 mg of TER or placebo were orally administered in a double-blind process to athletes who rested for 3 h, and then performed a battery of tests including a force–velocity exercise test, running sprint and a maximal endurance cycling test at Δ50 % (50 % between VT and ). Lactatemia, anaerobic parameters and endurance performance ( and time until exhaustion) were raised during the corresponding tests. We found that TER administration did not improve any of the parameters of aerobic performance ( p  > 0.05). In addition, no change in kinetic parameters was found with TER compared to placebo ( p  > 0.05). Moreover, no enhancement of the force–velocity relationship was observed during sprint exercises after TER intake ( p  > 0.05) and, on the contrary, maximal strength decreased significantly after TER intake ( p  < 0.05) but maximal power remained unchanged ( p  > 0.05). In conclusion, oral acute administration of TER at a supra-therapeutic dose seems to be without any relevant ergogenic effect on anaerobic and aerobic performances in healthy athletes. However, all participants experienced adverse side effects such as tremors.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1439-6319
1439-6327
1439-6327
DOI:10.1007/s00421-012-2447-0